Do you want to read an article? Please log in or register.
Effects of plaque brachytherapy and proton beam radiotherapy on prognostic testing: a comparison of uveal melanoma genotyped by microsatellite analysis
Ocular Oncology
Related content
Ocular Oncology
Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy
BMC Ophthalmol
Fang R, Wang H, Li Y, Liu YM, Wei WB
doi: 10.1186/s12886-021-01898-3
COMMENTED
Ocular Oncology
Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1001/jamaophthalmol.2019.5132.
Glaucoma and Ocular PressureOcular Oncology
Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects
Graefes Arch Clin Exp Ophthalmol.
Riechardt AI, Klein JP, Cordini D, Heufelder J, Rehak M, Seibel I, Joussen AM
doi: 10.1007/s00417-018-3929-5.
Ocular Oncology
Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients
Clin Exp Ophthalmol.
Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, Shields CL
doi: 10.1111/ceo.13758.
Ocular Oncology
Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Beam Therapy
Int J Radiat Oncol Biol Phys.
Lee HJ Jr, Stacey A, Klesert TR, Wells C, Skalet A, Bloch C, Fung A, Bowen SR, Wong TP, Shibata D, Halasz LM, Rengan R
doi: 10.1016/j.ijrobp.2019.02.005.
Ocular Oncology
Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D
Ophthalmology.
Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL
doi: 10.1016/j.ophtha.2019.04.027.
Macular DiseasesOcular OncologyRetinal Diseases
Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients
Br J Ophthalmol.
Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, Shields CL
doi: 10.1136/bjophthalmol-2019-314686.
Ocular Oncology
Genetic prognostication in uveal melanoma
Acta Ophthalmol.
Dogrusöz M, Jager MJ
doi: 10.1111/aos.13580.
Ocular Oncology
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Eur J Cancer.
Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C
doi: 10.1016/j.ejca.2017.05.038.